PMID- 36008064
OWN - NLM
STAT- MEDLINE
DCOM- 20220829
LR  - 20221207
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 12
IP  - 8
DP  - 2022 Aug 25
TI  - Effect of thiamine supplementation on glycaemic outcomes in adults with type 2 
      diabetes: a systematic review and meta-analysis.
PG  - e059834
LID - 10.1136/bmjopen-2021-059834 [doi]
LID - e059834
AB  - BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) have been shown to have 
      thiamine deficiency. Dietary supplementation is an economic strategy to control 
      blood glucose. Objective: To evaluate effectiveness of thiamine supplementation 
      on glycaemic outcomes in patients with T2DM. METHODS: Eligibility criteria: 
      Studies that assessed effect of thiamine supplementation in adults with T2DM 
      which measured glycaemic outcomes-HbA1c, fasting blood glucose (FBG) and/or 
      postprandial blood glucose (PPG) were included. Information sources: PUBMED, 
      Tripdatabase, the Cochrane Central Register, National Institute of Health 
      Clinical Database and Google Scholar were searched until December 2021 for RCTs. 
      Risk of bias: It was assessed using standardised critical appraisal instruments 
      from the Joanna Briggs Institute for RCTs. Synthesis of results: Where possible, 
      studies were pooled in a meta-analysis. Results were presented in a narrative 
      format if statistical pooling was not possible. RESULTS: Included studies: Six 
      trials involving 364 participants. Synthesis of results: No significant 
      beneficial effects were observed on glycaemic outcomes with 100-900 mg/day of 
      thiamine or benfotiamine for up to 3 months (HbA1c: MD, -0.02%, 95% CI: -0.35 to 
      0.31; FBG: MD,-0.20 mmol/L; 95% CI: -0.69 to 0.29; PPG: MD, - 0.20 mmol/L, 95% 
      CI: -2.05 to 1.65 (mean difference, MD)). There was a significant increase in 
      high-density lipoprotein (HDL) (MD, 0.10; 95% CI: 0.10 to 0.20) at 3-month 
      follow-up. Benfotiamine reduced triglyceride level (MD, -1.10; 95% CI: -1.90 to 
      -0.30) in 120 mg/day dose as compared with placebo 150 mg/day, however this was 
      not demonstrated in higher doses. DISCUSSION: Limitations of evidence: Inclusion 
      of single-centre trials published only in English, small sample sizes of included 
      studies, lack of trials investigating outcomes for same comparisons and varying 
      follow-up periods. Interpretation: Thiamine supplementation does not affect 
      glycaemic outcomes, however reduces triglycerides while increasing HDL. 
      Multicentre well-designed RCT with higher doses of thiamine and a follow-up 
      period of 1-2 years will provide better evidence. PROSPERO REGISTRATION NUMBER: 
      CRD42020170520.
CI  - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Muley, Arti
AU  - Muley A
AUID- ORCID: 0000-0002-0187-5728
AD  - Medicine, PIMSR, Parul University, Vadodara, Gujarat, India.
FAU - Fernandez, Ritin
AU  - Fernandez R
AD  - Nursing, University of Wollongong Faculty of Science Medicine and Health, 
      Wollongong, New South Wales, Australia Ritin.Fernandez@health.nsw.au.
FAU - Green, Heidi
AU  - Green H
AD  - Nursing, Centre for Research in Nursing and Health, St George Hospital, Sydney, 
      New South Wales, Australia.
FAU - Muley, Prasad
AU  - Muley P
AD  - Pediatrics, PIMSR, Parul University, Vadodara, Gujarat, India.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20220825
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - X66NSO3N35 (Thiamine)
SB  - IM
MH  - Adult
MH  - Blood Glucose
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Dietary Supplements
MH  - Glycated Hemoglobin
MH  - Humans
MH  - Thiamine/therapeutic use
PMC - PMC9422810
OTO - NOTNLM
OT  - General diabetes
OT  - Nutrition
OT  - Nutritional support
COIS- Competing interests: None declared.
EDAT- 2022/08/26 06:00
MHDA- 2022/08/30 06:00
PMCR- 2022/08/25
CRDT- 2022/08/25 21:06
PHST- 2022/08/25 21:06 [entrez]
PHST- 2022/08/26 06:00 [pubmed]
PHST- 2022/08/30 06:00 [medline]
PHST- 2022/08/25 00:00 [pmc-release]
AID - bmjopen-2021-059834 [pii]
AID - 10.1136/bmjopen-2021-059834 [doi]
PST - epublish
SO  - BMJ Open. 2022 Aug 25;12(8):e059834. doi: 10.1136/bmjopen-2021-059834.